Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021). In oral and […]
Philadelphia, PA, October 28, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5. SP-101, an investigational […]
Spirovant leases its new, expanded headquarters and laboratories in the robust gene and cell therapy epicenter of Philadelphia’s University City and welcomes the appointments of Eric Pastor as Senior Vice President of Technology Development and Operations and Maria Limberis, PhD, as Vice President of Research
Spirovant Sciences CEO Joan Lau selected to receive the Ernst & Young LLP (EY US) Entrepreneur of The Year 2020 Award in Greater Philadelphia by an independent panel of judges.
Spirovant announces that CEO Joan Lau, PhD, has been named a 2020 Woman of Distinction by the Philadelphia Business Journal. The award will be presented in a virtual ceremony on November 12 at 11 am.
Spirovant announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis.
Spirovant’s CEO, Joan Lau, PhD, has been named finalist for the Ernst & Young LLP (EY US) Entrepreneur of the Year 2020 Award in Greater Philadelphia, honoring entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world.
Spirovant Sciences today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery with 20+ years of research and executive leadership experience, most recently at MedImmune, AstraZeneca’s global biologics organization.